The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.
The group discusses considerations for educating and empowering patients receiving Bruton tyrosine kinase inhibitor (BTKi) therapy. As BTKis are given continuously long term, Dr Jacobs conceptualizes treatment as a marathon for patients. He emphasizes being upfront about common adverse effects and setting the expectation that doses can be reduced to mitigate toxicities without losing efficacy. This encourages patients to promptly communicate issues rather than try to push through them.
The experts recommend a patient-centered, shared decision-making approach involving the full care team, including pharmacy and nursing, to provide context and resources to help patients work through any adverse effects. Monitoring abandonment rates is also important to ensure patients from all backgrounds can remain on these long-term therapies. Effective patient education and support systems are crucial to facilitate optimal adherence throughout BTKi treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More